WASHINGTON (MedPage Today) -- The FDA has approved the histone deacetylase inhibitor belinostat for treatment of peripheral T-cell lymphoma, an uncommon but aggressive form of non-Hodgkin's lymphoma (NHL). via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment